WO2020060117A1 - 돼지 열병 백신용 조성물 및 이의 제조 방법 - Google Patents
돼지 열병 백신용 조성물 및 이의 제조 방법 Download PDFInfo
- Publication number
- WO2020060117A1 WO2020060117A1 PCT/KR2019/011915 KR2019011915W WO2020060117A1 WO 2020060117 A1 WO2020060117 A1 WO 2020060117A1 KR 2019011915 W KR2019011915 W KR 2019011915W WO 2020060117 A1 WO2020060117 A1 WO 2020060117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- fragment
- antigen
- promoter
- swine fever
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
- A61K39/225—Porcine transmissible gastroenteritis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/187—Hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Description
S/P value | |||||||||
Ag | 1w | 2w | 3w | 4w | 5w | 6w | 7w | Fn. | |
E2:CBD | Mouse 1 | -0.10 | 0.33 | 0.69 | 1.04 | 1.58 | 1.42 | 1.62 | 1.26 |
Mouse 2 | -0.01 | 0.32 | 0.82 | 0.87 | 0.84 | 0.89 | 0.63 | 0.72 | |
Mouse 3 | -0.07 | 0.90 | 0.89 | 0.80 | 0.85 | 1.21 | 1.41 | 1.47 | |
Mouse 4 | -0.04 | 0.21 | 0.31 | 0.25 | 0.30 | 0.35 | 0.43 | 1.15 | |
Mouse 5 | -0.07 | 0.14 | 0.31 | 0.46 | 0.74 | 0.96 | 1.08 | 0.96 | |
E2:pFc2 | Mouse 1 | 0.44 | 1.30 | 2.18 | 2.27 | 2.19 | 2.07 | 1.91 | 2.09 |
Mouse 2 | 1.15 | 1.75 | 2.65 | 3.14 | 3.23 | 2.82 | 2.87 | 2.80 | |
Mouse 3 | 0.06 | 0.57 | 1.25 | 1.40 | 1.17 | 1.08 | 1.11 | 1.06 | |
Mouse 4 | 0.40 | 1.72 | 2.66 | 2.59 | 2.58 | 2.55 | 2.49 | 3.10 | |
Mouse 5 | 0.44 | 1.54 | 3.00 | 2.55 | 2.66 | 2.71 | 2.43 | 2.95 |
실험차수 | 항원 | 개체번호 | 중화항체값 |
2-1차(2회 주사) | E2:CBD | 1 | 64 |
2 | 32 | ||
3 | 32 | ||
4 | 32 | ||
5 | 128 | ||
E2:pFc2 | 1 | 128 | |
2 | 256 | ||
3 | 32 | ||
4 | 256 | ||
5 | 512 | ||
2-2차(1회 주사) | E2:CBD | 1 | 4 |
2 | 4 | ||
3 | <4 | ||
4 | <4 | ||
5 | <4 | ||
E2:pFc2 | 1 | 256 | |
2 | 256 | ||
3 | 64 | ||
4 | 128 | ||
5 | 64 | ||
음성 | <4 | ||
양성 | 2048 |
일령 | 0주(1차접종) | 2주(2차접종) | 4주 | 6주 | 8주 | 10주 | 12주 | |
개체별 | 중화항체 | 중화항체 | 중화항체 | 중화항체 | 중화항체 | 중화항체 | 중화항체 | |
E2:pFc2 | #7 | 1 | <1 | 8 | 7 | 7 | 7 | 6 |
#8 | <1 | 1 | 9 | 8 | 7 | 8 | 6 | |
#9 | <4 | 4 | 8 | 7 | 6 | 5 | 5 | |
#10 | 2 | 4 | 10 | 9 | 7 | 7 | 6 | |
평균 | 1.5 | 2.25 | 8.75 | 7.75 | 6.75 | 6.75 | 5.75 |
Claims (16)
- 서열번호 4로 표시되는 돼지의 Fc 단편과 융합된 돼지 열병 항원 E2 단백질을 유효성분으로 포함하는, 돼지 열병 예방용 백신 조성물.
- 제 1 항에 있어서,상기 E2 단백질은 서열번호 18로 표시되는 아미노산 서열을 포함하는 것을 특징으로 하는, 백신 조성물.
- 제 1 항에 있어서,상기 E2 단백질은 Fc 단편과 융합됨으로써 자체 면역 증강 반응(self-adjuvanting) 효과 및 증가된 용해성을 가지는 것을 특징으로 하는, 백신 조성물.
- 서열번호 4로 표시되는 돼지의 Fc 단편과 융합된 돼지 열병 항원 E2 단백질을 유효성분으로 포함하는, 돼지 열병 예방용 사료 조성물.
- 서열번호 4로 표시되는 돼지의 Fc 단편을 코딩하는 폴리뉴클레오티드 및 돼지 열병 항원 E2 단백질을 코딩하는 폴리뉴클레오티드를 포함하는, Fc 단편과 융합된 돼지 열병 항원 E2 단백질 생산용 재조합 벡터.
- 제 5 항에 있어서,상기 E2 단백질은 서열번호 18로 표시되는 아미노산 서열을 포함하는 것을 특징으로 하는, 재조합 벡터.
- 제 5 항에 있어서,상기 재조합 벡터는 프로모터 유전자, 항원을 코딩하는 폴리뉴클레오티드 및 Fc 단편을 코딩하는 폴리뉴클레오티드가 순차적으로 연결되어 있는 것을 특징으로 하는, 재조합 벡터.
- 제 7 항에 있어서,상기 프로모터는 꽃양배추 모자이크 바이러스(cauliflower mosaic virus) 유래 35S 프로모터, 꽃양배추 모자이크 바이러스(cauliflower mosaic virus) 유래 19S RNA 프로모터, 식물의 액틴 단백질 프로모터, 유비퀴틴 단백질 프로모터, CMV(Cytomegalovirus) 프로모터, SV40(Simian virus 40) 프로모터, RSV(Respiratory syncytial virus) 프로모터, pEMU 프로모터, MAS 프로모터, 히스톤 프로모터, Clp 프로모터 및 EF-1a(Elongation factor-1 alpha) 프로모터로 이루어진 군으로부터 선택되는 어느 하나 이상인 것을 특징으로 하는, 재조합 벡터.
- 제 5 항에 있어서,상기 재조합 벡터는 BiP(Chaperone binding protein)를 코딩하는 폴리뉴클레오티드를 추가로 포함하는 것을 특징으로 하는, 재조합 벡터.
- 제 5 항에 있어서,상기 재조합 벡터는 HDEL(His-Asp-Glu-Leu) 펩타이드를 코딩하는 유전자를 추가로 포함하는 것을 특징으로 하는, 재조합 벡터.
- 제 5 항에 있어서,상기 재조합 벡터는 M17의 5' UTR(untranslational region) 부위 유전자를 추가로 포함하는 것을 특징으로 하는, 재조합 벡터.
- 제 5 항에 있어서,상기 재조합 벡터는 Fc 단편과 융합된 돼지 열병 항원 E2 단백질의 발현량을 증가시키는 것을 특징으로 하는, 재조합 벡터.
- 제 5 항 내지 제 12 항 중 어느 한 항의 재조합 벡터로 형질전환된, 형질전환체.
- (a) 제 13 항의 형질전환체를 배양하는 단계; 및(b) 상기 형질전환체 또는 배양액으로부터 Fc 단편이 융합된 돼지 열병 항원 E2 단백질을 분리 및 정제하는 단계를 포함하는, 자체-면역 증강 효과를 가지는 Fc 단편과 융합된 돼지 열병 항원 E2 단백질의 생산 방법.
- 서열번호 4로 표시되는 돼지의 Fc 단편과 융합된 돼지 열병 항원 E2 단백질을 유효성분으로 포함하는 조성물을 개체에 투여하는 단계를 포함하는 돼지 열병의 예방 또는 치료 방법.
- 서열번호 4로 표시되는 돼지의 Fc 단편과 융합된 돼지 열병 항원 E2 단백질을 유효성분으로 포함하는 조성물의 돼지 열병의 예방 또는 치료 용도.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201980016219.1A CN112135630B (zh) | 2018-09-19 | 2019-09-16 | 猪瘟疫苗组合物及其制备方法 |
US16/770,190 US11484589B2 (en) | 2018-09-19 | 2019-09-16 | Vaccine composition for classical swine fever and preparation method thereof |
JP2020521575A JP6993650B2 (ja) | 2018-09-19 | 2019-09-16 | 豚コレラワクチン用組成物およびその製造方法 |
BR112021005280-1A BR112021005280A2 (pt) | 2018-09-19 | 2019-09-16 | composição para vacina contra febre suína e método de preparação da mesma |
EP19862863.8A EP3854417A4 (en) | 2018-09-19 | 2019-09-16 | COMPOSITION FOR VACCINE AGAINST SWINE FEVER AND METHOD FOR PREPARATION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0112445 | 2018-09-19 | ||
KR1020180112445A KR102053009B1 (ko) | 2018-09-19 | 2018-09-19 | 돼지 열병 백신용 조성물 및 이의 제조 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020060117A1 true WO2020060117A1 (ko) | 2020-03-26 |
Family
ID=68837384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/011915 WO2020060117A1 (ko) | 2018-09-19 | 2019-09-16 | 돼지 열병 백신용 조성물 및 이의 제조 방법 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11484589B2 (ko) |
EP (1) | EP3854417A4 (ko) |
JP (1) | JP6993650B2 (ko) |
KR (1) | KR102053009B1 (ko) |
CN (1) | CN112135630B (ko) |
BR (1) | BR112021005280A2 (ko) |
WO (1) | WO2020060117A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102288367B1 (ko) * | 2018-11-15 | 2021-08-11 | 주식회사 바이오앱 | 식물체에서 바이러스-유사 입자를 발현하는 재조합 벡터 및 이를 이용한 써코바이러스-유사 입자를 포함하는 백신 조성물의 제조방법 |
KR102477054B1 (ko) * | 2020-03-24 | 2022-12-14 | 주식회사 바이오앱 | 웅취 제거용 재조합 단백질 및 이를 포함하는 백신 조성물 |
KR20210119231A (ko) | 2020-03-24 | 2021-10-05 | 주식회사 바이오앱 | 동물의 중성화용 재조합 단백질 및 이를 포함하는 백신 조성물 |
CN115073608B (zh) * | 2022-03-22 | 2023-05-02 | 广东海大集团股份有限公司 | 一种猪瘟病毒e2的核酸-蛋白复合标记性疫苗 |
CN114908056B (zh) * | 2022-05-18 | 2024-04-16 | 华中农业大学 | 一种表达猪PRV gDFc或gBFc融合蛋白的重组CHO细胞系及其构建方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150113934A (ko) * | 2014-03-31 | 2015-10-08 | 한미약품 주식회사 | 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법 |
KR101642727B1 (ko) | 2015-12-31 | 2016-07-27 | 대한민국 | 약독화된 돼지열병 바이러스 생마커백신주 및 이를 이용한 경구투여용 백신 조성물 |
CN106519041A (zh) * | 2016-11-24 | 2017-03-22 | 唐山怡安生物工程有限公司 | 猪免疫球蛋白Fc片段和猪瘟E2融合蛋白在CHO细胞株的构建方法及其制备方法和应用 |
KR101732624B1 (ko) * | 2014-12-22 | 2017-05-08 | 대한민국(농림축산식품부 농림축산검역본부장) | 식물 유래의 돼지 열병 백신용 조성물 및 이의 제조방법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105039406B (zh) * | 2015-07-10 | 2018-08-28 | 武汉中拓康明生物科技有限公司 | 一种猪IgG1 Fc重组杆状病毒作为猪用疫苗载体的制备方法 |
CN115073608B (zh) * | 2022-03-22 | 2023-05-02 | 广东海大集团股份有限公司 | 一种猪瘟病毒e2的核酸-蛋白复合标记性疫苗 |
-
2018
- 2018-09-19 KR KR1020180112445A patent/KR102053009B1/ko active IP Right Grant
-
2019
- 2019-09-16 WO PCT/KR2019/011915 patent/WO2020060117A1/ko unknown
- 2019-09-16 BR BR112021005280-1A patent/BR112021005280A2/pt unknown
- 2019-09-16 EP EP19862863.8A patent/EP3854417A4/en active Pending
- 2019-09-16 CN CN201980016219.1A patent/CN112135630B/zh active Active
- 2019-09-16 JP JP2020521575A patent/JP6993650B2/ja active Active
- 2019-09-16 US US16/770,190 patent/US11484589B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150113934A (ko) * | 2014-03-31 | 2015-10-08 | 한미약품 주식회사 | 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법 |
KR101732624B1 (ko) * | 2014-12-22 | 2017-05-08 | 대한민국(농림축산식품부 농림축산검역본부장) | 식물 유래의 돼지 열병 백신용 조성물 및 이의 제조방법 |
KR101642727B1 (ko) | 2015-12-31 | 2016-07-27 | 대한민국 | 약독화된 돼지열병 바이러스 생마커백신주 및 이를 이용한 경구투여용 백신 조성물 |
CN106519041A (zh) * | 2016-11-24 | 2017-03-22 | 唐山怡安生物工程有限公司 | 猪免疫球蛋白Fc片段和猪瘟E2融合蛋白在CHO细胞株的构建方法及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
DATABASE NCBI 12 January 2013 (2013-01-12), "IgG heavy chain precursor [Sus scrofa", XP055693893, Database accession no. BAM75542.1 * |
DATABASE NCBI 9 November 2012 (2012-11-09), "IgG heavy chain constant region, partial [Sus scrofa", XP055694632, Database accession no. BAM66310.1 * |
See also references of EP3854417A4 |
Also Published As
Publication number | Publication date |
---|---|
US20200289641A1 (en) | 2020-09-17 |
CN112135630A (zh) | 2020-12-25 |
US11484589B2 (en) | 2022-11-01 |
CN112135630B (zh) | 2024-02-27 |
JP2021508315A (ja) | 2021-03-04 |
KR102053009B1 (ko) | 2019-12-09 |
JP6993650B2 (ja) | 2022-01-13 |
EP3854417A4 (en) | 2022-07-20 |
BR112021005280A2 (pt) | 2021-06-29 |
EP3854417A1 (en) | 2021-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020060117A1 (ko) | 돼지 열병 백신용 조성물 및 이의 제조 방법 | |
KR101732624B1 (ko) | 식물 유래의 돼지 열병 백신용 조성물 및 이의 제조방법 | |
WO2017195919A1 (ko) | 식물 유래의 돼지 열병 백신용 조성물 및 이의 제조방법 | |
KR20190110605A (ko) | 돼지 코로나바이러스 백신 | |
WO2020159169A2 (ko) | 당화된 ag85a 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법 | |
US10857217B2 (en) | Antigen fused with porcine Fc fragment and vaccine composition comprising the same | |
WO2020213898A1 (ko) | 돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법 | |
WO2020059961A1 (ko) | 돼지의 fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물 | |
WO2020256374A1 (ko) | 아프리카 돼지열병의 예방을 위한 항원 생산용 재조합 벡터 및 이의 용도 | |
WO2020111814A1 (ko) | 광견병 예방용 백신 조성물 및 이의 제조 방법 | |
KR102444019B1 (ko) | 아프리카 돼지열병의 예방을 위한 항원 생산용 재조합 벡터 및 이의 용도 | |
WO2020256419A1 (ko) | 개 파보바이러스 감염증 치료를 위한 항체 생산용 재조합 벡터 및 이의 용도 | |
KR20200144506A (ko) | 개 파보바이러스 감염증 치료를 위한 항체 생산용 재조합 벡터 및 이의 용도 | |
KR20180114684A (ko) | 신규한 Stx2e 에피토프 단백질 및 이를 포함하는 백신 조성물 | |
KR100812637B1 (ko) | 항원 결정기를 포함하는 재조합 개 로타바이러스 vp4단백질 및 이에 대한 항체 | |
KR20230034141A (ko) | 아프리카 돼지열병 바이러스 유래 항원 단백질을 포함하는 아프리카 돼지열병의 예방용 백신 | |
CN117897171A (zh) | 包含源自非洲猪瘟病毒的抗原蛋白的用于预防非洲猪瘟的疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2020521575 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19862863 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021005280 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019862863 Country of ref document: EP Effective date: 20210419 |
|
ENP | Entry into the national phase |
Ref document number: 112021005280 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210319 |